Saad Z. Usmani MD MBA FASCO 🇺🇸🇵🇰 (@szusmani) ranks #16 among US multiple myeloma KOLs on X in 2026, by engagement from fellow physicians. 9 physicians shared, quoted or replied to their posts this year. CMS Open Payments lists $77,732 in 2025 general payments.
At a Glance
- Multiple Myeloma: US #16, Global #19 · 9 physicians engaged
- Presented at ASH 2025, ASCO 2026, EHA 2026, IMS 2026 in 2026
- CMS Open Payments lists $77,732 in 2025 general payments.
This Month
What Saad Z. Usmani MD MBA FASCO 🇺🇸🇵🇰 has posted in the last 30 days. Updated November 11, 2026.
No trial posts in the last 30 days.
2026 Rankings
| List | US rank | Global rank | Peer Engagement Score | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|---|
| Multiple Myeloma | #16 | #19 | 54/100 | 9 | 21 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Saad Z. Usmani MD MBA FASCO 🇺🇸🇵🇰 presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- ASH 2025 · Oral (abstract 698)RedirecTT-1: talquetamab + teclistamab in RRMM with extramedullary diseaseSource: IMF blog ↗
- ASH 2025 · Oral (abstract 250)Phase 1 study of KTX-1001, an oral MMSET/NSD2 inhibitor, in RRMMSource: IMF blog ↗
- ASCO 2026 · Oral (rapid oral)CEPHEUS final update: D-VRd vs VRd in transplant-ineligible NDMM
- ASCO 2026 · OralDREAMM-9 final results: belantamab mafodotin + VRd in transplant-ineligible NDMM
- EHA 2026 · Oral (abstract S196)CEPHEUS final analysis: dara-VRd in transplant-ineligible NDMM
- IMS 2026 · Oral (abstract OA-20)DREAMM-9 patient-reported vision-related function with extended belantamab dosing intervals
What Colleagues Are Saying About Saad Z. Usmani MD MBA FASCO 🇺🇸🇵🇰
2026 posts by fellow physicians that mention @szusmani, quoted word for word.
Just out in @NEJM Effective therapy of extra medullary relapsed myeloma with teclistamab plus talquetamab (Tec-Tal). RedirecTT-1 #ASH25 @myelomaMD @szusmani @mvmateos 80% response rate. 60% PFS at 12 months. https://t.co/fqAPu4pMUc
A simultaneous presentation and NEJM publication for ReDirecTT-1: Tec + Tal in EMD by @szusmani n=90; ORR 79% 12-month PFS 57.5% Grade 3+ infections 32%. 8 discontinuations due to AEs. 10 AE-related deaths. Overall, amazing to have a dedicated EMD study. This is truly a https://t.co/MtyyykgQ8u
#ASH25 congrats @szusmani @myelomaMD et al: EXCELLENT RedirecTT-1!! True hope for true EMD 👏 I agree with Ben & will add Consort from @NEJM - no attrition due to PD/death with off-the-shelf bsAb duo. Peri-CAR-T holding & bridging so hard in true EMD. Maybe we don’t need to! https://t.co/LqiXMLplPg https://t.co/ho06P2SZ2w
#ASCO26 #mmsm Oral sessions myeloma DREAMM-9 final analysis @szusmani All cohorts and doses summarize below https://t.co/tHMXuUuZdi
PFS not reached in 15 months follow up of RedirecTT-1 in #myeloma with extramedullary disease. Presented by @szusmani #ASH25 Also published in NEJM: https://t.co/rBA7UF55kU https://t.co/Cqbc2FYGi8
Industry Payments
CMS Open Payments · 2025 general payments
$77,732 across 51 payments